Antiviral Therapies for Adults With Mild to Moderate COVID-19 Infection.

IDSA recommends antiviral treatments for mild to moderate COVID-19 in adults, updating guidelines for 2025 to improve patient outcomes.

• Why it matters: Effective antiviral therapies are crucial to reduce disease progression and transmission, yet optimal treatment strategies for mild to moderate cases remain unclear.
• What they did: The 2025 IDSA guidelines review and synthesize current evidence, providing updated recommendations on antiviral use for adult patients with mild to moderate COVID-19.
• The result: These updated guidelines aim to standardize care, enhance treatment efficacy, and inform clinicians on best practices for managing COVID-19 in non-severe cases.